YK 4-279

12/29/2021 - "In a previous study, we discovered the small molecule drug YK-4-279 almost completely inhibited tumor progression in the BrafCA;Tyr-CreERT2;Ptenflox/flox transgenic mouse model. "
12/29/2021 - "While the MOCK mice had progression of tumors, both YK-4-279 and YK-4-279 delay groups had a significant block or delay of progression. "
01/01/2021 - "Moreover, YK-4-279 significantly inhibited tumor growth and induced apoptosis in a xenograft mice model. "
10/30/2020 - "Here we aimed to identify molecular factors underlying YK-4-279 responsiveness in ETS fusion-negative cancers. "
01/01/2019 - "Knock-down experiments and ChIP corroborated the notion of a functional role for ETS1 and, accordingly, all double-mutant tumor cells were highly sensitive towards the ETS-factor inhibitor YK-4-279. "

07/01/2015 - "By advancing an oral formulation of YK-4-279 and identifying prominent mechanisms of resistance, this preclinical research takes us one step closer to a shared goal of curing adolescents and young adults afflicted by Ewing sarcoma."
07/01/2015 - "An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma."
10/30/2020 - "The small-molecule E26 transformation-specific (ETS) factor inhibitor YK-4-279 was developed for therapy of ETS/EWS fusion-driven Ewing's sarcoma. "
07/01/2015 - "Daily enteral administration of YK-4-279 led to significant delay in Ewing sarcoma tumor growth within a murine model. "
11/10/2015 - "We identified a small molecule, YK-4-279, that directly binds to EWS-FLI1 and inhibits its oncogenic activity in Ewing sarcoma cell lines and xenograft mouse models. "

11/10/2015 - "Herein, we tested in vivo therapeutic efficacy and potential side effects of YK-4-279 in the transgenic mouse model with EWS-FLI1 induced leukemia. "
11/10/2015 - "YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model."

01/01/2017 - "The aim of the current study was to determine the effects of the ERG small-molecule inhibitor YK-4-279 on ERG+ prostate cancer patient-derived xenografts (PDX). "
01/01/2017 - "Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279."
01/01/2017 - "YK-4-279 is a small molecule inhibitor of ETV1 that plays an important role in the progression of prostate cancer. "
01/01/2014 - "Therefore, YK-4-279 or similar compounds may be evaluated as a potential therapeutic tool for treatment of human prostate cancer at different stages."
01/01/2014 - "We recently demonstrated that the small molecule YK-4-279 inhibits biological activity of ETV1 in fusion-positive prostate cancer cells leading to decreased motility and invasion in-vitro. "

01/01/2021 - "In this study we aimed to investigate whether TERT promoter mutations confer sensitivity to ETS inhibitor YK-4-279 in thyroid cancer cells and whether this inhibitor could be served as a potential therapeutic agent for thyroid cancer. "
01/01/2021 - "In vitro assays showed that YK-4-279 treatment sharply suppressed cell viability, colony formation, migration, and invasion, as well as induced cell cycle arrest and apoptosis in a panel of thyroid cancer cells. "
01/01/2021 - "The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of TERT Promoter Mutations."
01/01/2021 - "Thus, ETS inhibitor YK-4-279 suppressed TERT expression and conferred anti-tumor activity in a TERT promoter mutation-independent manner, and it could be a potential agent for the treatment of advanced thyroid cancers."